Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor

Award Information
Agency:
Department of Health and Human Services
Amount:
$2,053,613.00
Program:
STTR
Contract:
1R42HL112518-01
Solitcitation Year:
2012
Solicitation Number:
PA11-097
Branch:
N/A
Award Year:
2012
Phase:
Phase I
Agency Tracking Number:
R42HL112518
Solicitation Topic Code:
NHLBI
Small Business Information
OCEAN NANOTECH, LLC
2143 Worth Lane, SPRINGDALE, AR, -
Hubzone Owned:
N
Woman Owned:
Y
Socially and Economically Disadvantaged:
N
Duns:
155516987
Principal Investigator
 Y WANG
 (479) 751-5500
 awang@oceannanotech.com
Business Contact
 ALICE BU
Phone: (479) 751-5500
Email: alicebu@oceannanotech.com
Research Institution
 UNIVERSITY OF WASHINGTON
 UNIVERSITY OF WASHINGTON
Office of Sponsored Programs 4333 Brooklyn Ave NE Box 359472
SEATTLE, WA, 98195-9472
 () -
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Chest pain in patients presenting to the emergency department (ED) present a clinical dilemma: transfer for emergent coronary revascularization, admit overnight for cardiac telemetry and stress testing, or discharge home with medical follow-up. In this proposal, we hypothesize that a novel thrombus-specific Spectral Computed Tomography (Multicolored CT) nanoparticle (i.e., NanoK) approach for direct rapid assessment of coronary disease in the ED could help resolve this clinical dilemma. This project, which is led by Ocean NanoTech in collaboration with Washington University, will complete development of a GLP-/GMP-ready 1- fibrin NanoK product candidate suitably advanced for GLP stability and toxicity testing to support an FDA IND. This NanoK platform technology offers unique benefits for diagnosis and treatment of acute coronary disease that could improve healthcare outcomes and reduce costs. PUBLIC HEALTH RELEVANCE: Chest pain in patients presenting to the emergency department (ED) present a clinical dilemma: transfer for emergent coronary revascularization, admit overnight for cardiac telemetry and stress testing, or discharge home with medical follow-up. While the emergent need for cardiac catheterization is selfevident from the presentation of some individuals, the determination of whether to admit or discharge a patient with an equivocal history and physical is often problematic. In lieu of missing a critical cardiac diagnosis, patients are admitted for myocardial evaluation and stress testing, which is inconvenient, costly and unnecessary in the majority of cases. In this proposal, we hypothesize that a novel thrombus-specific Spectral Computed Tomography (Multicolored CT) nanoparticle (i.e., NanoK) approach for direct rapid assessment of coronary disease in the ED could help resolve this clinical dilemma. This project describes the demonstration of the prototype concept in Phase 1 and the development, demonstration, and characterization of the clinical productcandidate in Phase II. The overarching goal of this project, which is led by Ocean NanoTech in collaboration with Washington University, will be to complete development of a GLP- /GMP-ready 1-fibrin NanoK product candidate suitably advanced for GLP stability and toxicity testing to support an FDA IND. This NanoK platform technology offers unique benefits for diagnosis and treatment of acute coronary disease that could improve healthcare outcomes and reduce costs.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government